TCL Archive Conversation with The Cancer Letter: Kazerooni: The Case for Broad Coverage March 21, 2014
TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products. April 22, 2005
